Overview

Myelofibrosis is a kind of bone marrow cancer. Bone marrow is the soft matter inside the bones where blood cells are made. Myelofibrosis causes scarring in the bone marrow. This makes it hard for the bone marrow to make healthy blood cells.

Myelofibrosis sometimes happens on its own. This is called primary myelofibrosis. Sometimes it's caused by another blood cell condition. When this happens, it's called secondary myelofibrosis.

Some people with myelofibrosis have no symptoms and might not need treatment right away. Others with more-serious forms of the disease might need treatment. Treatment for myelofibrosis typically focuses on relieving symptoms.

Myelofibrosis belongs to a group of cancers called myeloproliferative neoplasms. These cancers cause the body to make too many blood cells that don't work right. Myelofibrosis and the other myeloproliferative neoplasms can lead to different types of leukemia. Leukemia is cancer that affects the blood-forming tissues in the body.

Symptoms

Myelofibrosis signs and symptoms may include:

  • Feeling tired, weak or short of breath.
  • Pain or fullness below the ribs on the left side.
  • Easy bruising.
  • Easy bleeding.
  • Sweating a lot while sleeping, so that you wake feeling covered in sweat.
  • Fever.
  • Bone pain.
  • Feeling full after eating a small amount of food.

When to see a doctor

Make an appointment with a doctor or other healthcare professional if you have any symptoms that worry you.

Causes

It's often not clear what causes myelofibrosis. This cancer happens in the bone marrow. Bone marrow is the soft matter inside the bones where blood cells are made.

The bone marrow makes cells called blood stem cells that can become other kinds of cells. When needed, these stem cells can turn into the blood cells that circulate through the body. Blood stem cells can become:

  • Red blood cells that carry oxygen to the body.
  • White blood cells that help fight infections.
  • Platelets that help stop bleeding.

Myelofibrosis starts when blood stem cells in the bone marrow develop changes in their DNA. A cell's DNA holds the instructions that tell the cell what to do. In healthy blood stem cells, the DNA gives instructions to turn into blood cells in a controlled way.

In myelofibrosis, the DNA changes give different instructions to the blood stem cells. The changes tell the blood stem cells to make more blood cells than the body needs. The blood cells don't work like healthy blood cells.

Myelofibrosis also causes scarring in the bone marrow. The scarring makes it hard for the bone marrow to make healthy blood cells.

The extra blood cells that don't work right and the bone marrow scarring both can cause too few healthy blood cells in the body. This leads to the symptoms of myelofibrosis. For example, feeling weak and tired can happen if there are too few red blood cells to carry oxygen in the blood.

Healthcare professionals have discovered some genetic changes in the DNA that can cause myelofibrosis, including changes to the:

  • Janus kinase 2 gene, also called JAK2.
  • Calreticulin gene, also called CALR.
  • Thrombopoietin receptor gene, also called MPL.

Your healthcare team might test your cancer cells to see if these changes are present. The results can impact your prognosis and your treatment options.

Risk factors

Although the cause of myelofibrosis often isn't known, healthcare professionals have found some things that might raise the risk. Risk factors include:

  • Increasing age. Myelofibrosis can affect anyone, but it's most often diagnosed in people older than 50.
  • Another blood cell condition. A small portion of people with myelofibrosis develop the condition as a complication of essential thrombocythemia or polycythemia vera.
  • Exposure to benzene. Myelofibrosis has been linked to high levels of exposure to the industrial chemical benzene.
  • Exposure to radiation. People exposed to very high doses of radiation have an increased risk of myelofibrosis.

Complications

Complications that may result from myelofibrosis include:

Enlarged spleen

People with myelofibrosis often have an enlarged spleen. The spleen is tucked below the rib cage on the left side of the belly. This organ has many jobs, including storing extra blood cells. In myelofibrosis, extra blood cells made by the bone marrow can build up in the spleen. This causes it to swell. The spleen also might start making blood cells if myelofibrosis causes severe scarring in the bone marrow. This creates more cells that can cause the spleen to swell. When the spleen swells it becomes enlarged. A severely enlarged spleen can cause belly pain and feeling full after eating only a little food.

Portal hypertension

Portal hypertension is the medical term for increased pressure in the portal vein. The portal vein brings blood to the liver. If an enlarged spleen is sending more blood than usual to the liver, it may cause pressure in the portal vein. Pressure in the portal vein can force blood into smaller veins and cause bleeding in the stomach and esophagus.

Growths in other areas of the body

If myelofibrosis makes it hard for the bone marrow to make blood cells, other organs might start making blood cells. The liver and spleen might start making blood cells. Growths of tissue that can make blood cells might form in other areas of the body. This can lead to bleeding in the digestive system, coughing or spitting up blood, compression of the spinal cord, or seizures.

Bleeding complications

Myelofibrosis makes it hard for the body to make healthy platelets. Platelets are blood cells that help stop bleeding. If you have too few healthy platelets, you might bruise more easily. You also could have an increased risk of dangerous bleeding.

Leukemia

Some people with myelofibrosis develop acute myelogenous leukemia. This is a type of blood and bone marrow cancer that often gets worse quickly.

May 02, 2025

Living with myelofibrosis?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

Lori, Volunteer Mentor
My Bone Marrow Transplant (BMT/SCT) story: Will you share yours?

675 Replies Thu, May 01, 2025

hikerny
Anyone have chronic lymphocytic leukemia (CLL)?

46 Replies Thu, May 01, 2025

cdurbin
What are most common side effects when starting HU (Hydroxyurea)?

164 Replies Wed, Apr 30, 2025

See more discussions
  1. Myeloproliferative neoplasms. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477. Accessed Dec. 10, 2024.
  2. Tefferi A. Myelofibrosis (MF): Management of primary MF and secondary MF. https://www.uptodate.com/contents/search. Accessed Dec. 10, 2024.
  3. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk stratification and management. American Journal of Hematology. 2023; doi:10.1002/ajh.26857.
  4. Hoffman R, et al., eds. Primary myelofibrosis and chronic neutrophilic leukemia. In: Hematology: Basic Principles and Practice. 8th ed. Elsevier; 2023. https://clinicalkey.com. Accessed Dec. 18, 2024.
  5. Palliative care. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed Dec. 12, 2024.
  6. Ferri FF. Primary myelofibrosis. In: Ferri's Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Dec. 18, 2024.
  7. Gulati V, et al. Sclerotic bone lesions caused by non-infectious and non-neoplastic diseases: A review of the imaging and clinicopathologic findings. Skeletal Radiology. 2021; doi:10.1007/s00256-020-03644-0.
  8. Tefferi A. Overview of the myeloproliferative neoplasms. https://www.uptodate.com/contents/search. Accessed Dec. 23, 2024.
  9. Emotions and cancer. National Cancer Institute. https://www.cancer.gov/about-cancer/coping/feelings. Accessed Dec. 28, 2024.
  10. Chronic myeloproliferative neoplasms treatment (PDQ) – Patient version. National Cancer Institute. https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq. Accessed Dec. 29, 2024.
  11. Tefferi A. Clinical manifestations and diagnosis of primary myelofibrosis. https://www.uptodate.com/contents/search. Accessed Dec. 31, 2024.
  12. Tefferi, A. Pathogenetic mechanisms in primary myelofibrosis. https://www.uptodate.com/contents/search. Accessed Jan. 3, 2025.
  13. Kaushansky K, et al., eds. Primary myelofibrosis. In: Williams Hematology. 10th ed. McGraw Hill; 2021. https://accessmedicine.mhmedical.com. Accessed Dec. 17, 2024.
  14. Portal hypertension. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/portal-hypertension. Accessed Jan. 2, 2025.
  15. Spleen. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/spleen. Accessed Jan. 2, 2025.
  16. Pruthi RKK (expert opinion). Mayo Clinic. Jan. 31, 2025.